Current Value
$1.731 Year Return
Current Value
$1.731 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| DBB | 0.08% | $117.01M | 0.77% |
| VDC | -0.09% | $7.60B | 0.09% |
| IXC | 0.14% | $1.73B | 0.41% |
| XONE | 0.32% | $625.28M | 0.03% |
| SPIP | -0.32% | $969.51M | 0.12% |
| VDE | -0.32% | $7.00B | 0.09% |
| VNM | -0.34% | $421.77M | 0.68% |
| JMST | -0.37% | $4.06B | 0.18% |
| FXN | -0.42% | $277.65M | 0.62% |
| CGSM | 0.43% | $709.45M | 0.25% |
| GOVT | 0.44% | $27.54B | 0.05% |
| FENY | -0.50% | $1.29B | 0.084% |
| KRBN | -0.51% | $160.17M | 0.85% |
| RSPG | -0.52% | $428.86M | 0.4% |
| KCCA | 0.66% | $109.43M | 0.87% |
| SHM | 0.66% | $3.41B | 0.2% |
| FCG | -0.68% | $334.91M | 0.57% |
| PWZ | 0.71% | $759.91M | 0.28% |
| FSTA | -0.79% | $1.35B | 0.084% |
| BSMW | 0.88% | $107.45M | 0.18% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CLFD | 32.59% | $606.07M | +17.01% | 0.00% |
| OKLO | 32.31% | $7.50B | +522.18% | 0.00% |
| EYPT | 29.26% | $664.72M | +12.07% | 0.00% |
| NNOX | 28.61% | $339.85M | -24.50% | 0.00% |
| ACET | 26.66% | $50.78M | -43.67% | 0.00% |
| TLPH | 26.37% | $9.25M | -50.98% | 0.00% |
| AB | 26.24% | $4.57B | +21.69% | 8.09% |
| FOLD | 26.09% | $1.83B | -39.35% | 0.00% |
| BTBT | 26.01% | $745.69M | -19.82% | 0.00% |
| IRDM | 25.92% | $3.41B | +17.52% | 1.76% |
| WRAP | 25.87% | $78.39M | -14.84% | 0.00% |
| BIP | 25.51% | $15.61B | +17.61% | 4.92% |
| OCUL | 25.43% | $1.51B | +41.41% | 0.00% |
| NNDM | 25.15% | $336.79M | -38.49% | 0.00% |
| TSM | 25.06% | $1.21T | +28.01% | 1.14% |
| PLRX | 24.78% | $73.66M | -88.66% | 0.00% |
| MGTX | 24.58% | $556.13M | +72.14% | 0.00% |
| AUTL | 24.53% | $625.43M | -32.66% | 0.00% |
| CMBM | 24.41% | $11.39M | -82.98% | 0.00% |
| VTYX | 24.36% | $143.75M | -9.01% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PPC | -15.49% | $10.84B | +33.46% | 0.00% |
| FI | -13.83% | $95.61B | +15.90% | 0.00% |
| MOH | -13.55% | $12.95B | -19.36% | 0.00% |
| CL | -13.20% | $74.88B | -3.64% | 2.19% |
| GIS | -12.67% | $29.20B | -14.66% | 4.47% |
| CNC | -12.08% | $16.81B | -49.40% | 0.00% |
| PEP | -11.20% | $187.12B | -16.06% | 4.02% |
| ARCO | -11.14% | $1.64B | -14.10% | 3.08% |
| STNG | -10.73% | $2.14B | -48.70% | 3.80% |
| BG | -10.42% | $10.94B | -25.60% | 3.39% |
| VZ | -10.38% | $183.79B | +6.01% | 6.18% |
| CAG | -10.32% | $10.09B | -24.85% | 6.62% |
| MKC | -10.15% | $20.55B | +9.57% | 2.30% |
| HSY | -10.13% | $35.88B | -3.63% | 3.10% |
| AEP | -10.02% | $55.16B | +17.93% | 3.54% |
| ELV | -9.75% | $79.13B | -33.96% | 1.88% |
| POST | -9.57% | $6.21B | +6.74% | 0.00% |
| AWK | -9.51% | $27.36B | +9.65% | 2.21% |
| EOG | -9.02% | $67.07B | -3.07% | 3.07% |
| PGR | -8.88% | $151.13B | +22.60% | 1.89% |
Yahoo
Aprea Therapeutics (APRE) said Wednesday that initial data from a phase 1 trial showed that APR-1051
Yahoo
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Yahoo
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051 DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer
Yahoo
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7%, 14% and 21% ACESOT-1051, the Phase 1 trial of WEE1 inhibitor APR-1051, continues to advance, with patients now being dosed at 100 mg once daily $19.3 million in cash and cash equivalen
Yahoo
According to the company, the trial’s open-label data is anticipated in the latter half of this year.
Yahoo
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that a patient with HPV+ head an
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -15.66% | $296.22M | 1.43% |
| VIXY | -14.19% | $164.54M | 0.85% |
| DBE | -13.69% | $52.20M | 0.77% |
| SOYB | -13.24% | $26.67M | 0.22% |
| TAIL | -12.03% | $99.63M | 0.59% |
| PDBC | -11.45% | $4.42B | 0.59% |
| UGA | -11.44% | $72.33M | 0.97% |
| SGOV | -11.44% | $49.21B | 0.09% |
| USDU | -11.15% | $162.43M | 0.5% |
| USL | -11.04% | $42.23M | 0.85% |
| OILK | -11.02% | $71.87M | 0.69% |
| BNO | -10.87% | $103.79M | 1% |
| COMT | -10.79% | $604.69M | 0.48% |
| DBC | -10.72% | $1.23B | 0.87% |
| USO | -10.49% | $1.13B | 0.6% |
| DBO | -10.30% | $228.24M | 0.77% |
| CCOR | -10.14% | $51.66M | 1.18% |
| GSG | -9.98% | $959.40M | 0.75% |
| CANE | -9.89% | $10.37M | 0.29% |
| UUP | -8.26% | $201.63M | 0.77% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| NUKZ | 29.82% | $374.23M | 0.85% |
| FFTY | 25.98% | $81.20M | 0.8% |
| IWC | 25.01% | $818.14M | 0.6% |
| URA | 24.88% | $3.82B | 0.69% |
| SIXG | 24.86% | $628.37M | 0.3% |
| ITEQ | 24.58% | $98.58M | 0.75% |
| RDTE | 24.55% | $137.93M | 0.97% |
| IZRL | 24.50% | $116.38M | 0.49% |
| SWAN | 24.34% | $252.67M | 0.49% |
| IWMY | 24.05% | $119.32M | 1.02% |
| ARTY | 23.84% | $1.09B | 0.47% |
| PRNT | 23.50% | $76.77M | 0.66% |
| JPIB | 23.43% | $910.86M | 0.5% |
| ARKG | 23.31% | $1.02B | 0.75% |
| ICVT | 23.01% | $2.53B | 0.2% |
| BLCN | 22.97% | $47.52M | 0.68% |
| IHAK | 22.95% | $951.11M | 0.47% |
| CIBR | 22.85% | $10.06B | 0.59% |
| ARKX | 22.82% | $341.31M | 0.75% |
| XSW | 22.82% | $499.42M | 0.35% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KLAC | -<0.01% | $121.81B | +7.94% | 0.74% |
| BR | 0.01% | $27.96B | +19.31% | 1.47% |
| PACS | 0.02% | $2.02B | -56.52% | 0.00% |
| BLDR | -0.03% | $14.13B | -4.83% | 0.00% |
| CWEN.A | 0.03% | $3.56B | +34.52% | 5.66% |
| SD | -0.04% | $406.86M | -15.21% | 4.00% |
| POOL | -0.05% | $11.38B | +0.52% | 1.62% |
| ABBV | -0.06% | $336.94B | +16.42% | 3.35% |
| LTM | -0.06% | $12.63B | -95.46% | 2.42% |
| SNAP | -0.08% | $15.68B | -40.44% | 0.00% |
| KSS | -0.09% | $1.03B | -57.13% | 13.36% |
| CVI | 0.10% | $2.97B | +11.17% | 1.69% |
| HTHT | 0.10% | $10.27B | -0.42% | 2.94% |
| MCK | -0.10% | $88.11B | +20.93% | 0.40% |
| BBU | -0.11% | $2.34B | +39.20% | 0.96% |
| AVD | 0.11% | $140.05M | -52.08% | 0.00% |
| VIST | -0.11% | $4.60B | +6.03% | 0.00% |
| SW | 0.12% | $24.63B | +2.08% | 3.10% |
| VSA | -0.12% | $8.67M | -19.04% | 0.00% |
| PLCE | -0.12% | $107.07M | -37.44% | 0.00% |
